Herbal capsule aims to tackle both high blood pressure and poor sleep

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 18-79 years (inclusive), male or female; 2. Meet diagnostic criteria for essential hypertension, and satisfy one of the following conditions: Grade 1 hypertension with no antihypertensive drugs in the past 2 weeks; Receiving stable treatment with one standard-dose chemical antihypertensive agent for at least 4 weeks, with blood pressure（BP）140-159/90-99 mmHg, and is willing to maintain the treatment regimen without adjustment; 3. Insomnia Serverity Index (ISI) score ≥ 8, symptoms occur for at least 3 nights per week and have persisted for no less than 3 months; 4. No sedative-hypnotic drugs have been taken within the preceding one month; 5. Is able to complete scale assessments independently; 6. Is willing and able to comply with all examinations and observations specified in the protocol; Has provided written informed consent. Exclusion Criteria: 1. Severe hypertension (mean SBP ≥ 180 mmHg and/or mean DBP ≥ 110 mmHg); malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc. 2. Suspected secondary hypertension (renal parenchymal hypertension, renovascular hypertension, obstructive sleep apnea, primary aldosteronism or other endocrine hypertension, drug-induced hypertension, monogenic hypertension, etc.); 3. Clinically significant laboratory abnormalities at screening: ALT \> 1.5 × ULN, AST \> 1.5 × ULN, or Serum creatinine ≥ 2.0 mg/dL; 4. Chronic gastrointestinal disorders accompanied by frequent abdominal pain or diarrhea, or history of gastrointestinal surgery that may impair drug absorption; 5. A history of allergic diathesis or hypersensitivity to any component of the investigational product; 6. Pregnant females，or those with a positive pregnancy test at screening, women planning pregnancy during the study, lactating women, or fertile women without adequate contraception protection; 7. Clinically severe and unstable hepatic, renal, hematologic disease, malignant tumor, or unilateral/bilateral renal artery stenosis; 8. Documented psychiatric disorder, or GAD-7 score ≥ 10 or PHQ-9 score ≥ 10; 9. Insomnia due to hyperthyroidism, restless legs syndrome, narcolepsy, sleep-related movement disorders, etc.; 10. Insomnia due to neurodegenerative diseases (Parkinson's disease, Alzheimer's disease, epilepsy, etc.); 11. Acute stroke; 12. Confirmed diagnosis of OSA or STOP-BANG score ≥ 5; 13. Night shift or rotating shift workers; 14. Suspected or confirmed alcohol or drug abuse/dependence; 15. Participation in another clinical trial within 3 months prior to screening; Any other condition deemed by the investigator to render the subject unsuitable for the trial.